Targeting the Non-Canonical Phosphoinositide Kinases in P53 Mutant Breast Cancer
Abstract
The ultimate goal and the overall impact of this project are to characterize PI5P4Ks as a novel liability for breast tumors with TP53 mutations in order to define opportunities for therapeutic intervention for breast cancer patients with these mutations, which currently lack targeted therapy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2020
- Accession Number
- AD1118639
Entities
People
- Brooke M Emerling
Organizations
- Sanford Burnham Prebys Medical Discovery Institute